Question 1

How do I know if a stem cell provider is operating legally in the United States?

Accepted Answer

In the U.S., check compliance with FDA 21 CFR Part 1271. Products that qualify under Section 361 (HCT/Ps) must meet two criteria: minimal manipulation and homologous use. If a provider offers lab-expanded cells, systemic IV infusions for general wellness, or claims to cure conditions like Parkinson's or diabetes without an active FDA Investigational New Drug (IND) authorization, they are operating outside federal guidelines. Ask directly whether the product is regulated under Section 361 (tissue) or Section 351 (drug). A provider who cannot answer that question clearly does not understand their own regulatory position.

Question 2

What is the difference between an FDA-Registered facility and an FDA-Approved product?

Accepted Answer

They are not related. FDA-Registered means a facility submitted basic administrative paperwork listing its address and tissue activities under 21 CFR 1271. It involves no scientific testing, no safety vetting, and no clinical trial review. FDA-Approved means a specific biological product underwent years of multi-phase clinical trials to establish safety and efficacy. Providers who advertise being FDA Registered in a way that implies approval are conflating the two, and it is one of the most common forms of misleading marketing in this field.

Question 3

What does the FDA mean by 'minimal manipulation'?

Accepted Answer

Under 21 CFR 1271.3(f), the definition depends on tissue type. For structural tissues such as bone, skin, or amniotic membrane, minimal manipulation means processing that does not alter the original characteristics relating to reconstruction, repair, or replacement. For cellular tissues, it means processing that does not alter the relevant biological characteristics of the cells. Grinding, crushing, or enzymatic digestion of structural tissue generally crosses into more than minimal manipulation, which changes how the product is regulated.

Question 4

Why is injecting amniotic or perinatal tissue into a joint considered non-homologous use?

Accepted Answer

Homologous use means the product performs the same basic function in the recipient that it performed in the donor. Amniotic fluid's native function is to cushion and protect a developing fetus. Injecting it into a knee to address osteoarthritis or act as a joint lubricant is a fundamentally different purpose. The FDA treats that as non-homologous use, which moves the product out of the 361 tissue pathway and into the 351 biologic drug pathway.

Question 5

Is it legal to offer IV infusions of cell products for anti-aging or general wellness?

Accepted Answer

Intravenous administration of umbilical cord tissue, amniotic fluid, or cultured cells for non-homologous purposes such as anti-aging, systemic inflammation, or cognitive enhancement is classified by the FDA as an unapproved biologic drug therapy. The FDA has issued explicit safety warnings noting that IV infusion of unapproved cellular products carries risks including pulmonary embolism, severe allergic reaction, and immune rejection.

Question 6

Can umbilical cord blood be marketed as a stem cell therapy for anti-aging?

Accepted Answer

No. The FDA's position is that cord blood marketed for systemic, non-homologous uses such as anti-aging, neurological conditions, or immune modulation does not meet the criteria for a 361 HCT/P and is an unapproved biologic drug. The only FDA-approved use of cord blood-derived hematopoietic stem cells is for specific blood-forming disorders.

Question 7

What is the Corporate Practice of Medicine doctrine, and why does it matter?

Accepted Answer

CPOM is a legal principle adopted in many states prohibiting non-physicians and business corporations from practicing medicine or directing clinical care. In regenerative medicine it matters because it is the safeguard ensuring that the decision about whether you are a candidate is made by a licensed physician exercising independent judgment, not by a sales team working against a revenue target. When you evaluate any provider, it is worth asking who makes the candidacy decision and whether that person has anything to gain from the answer being yes.

Question 8

What is the difference between cGTP and cGMP?

Accepted Answer

Current Good Tissue Practices (cGTP) are FDA regulations governing methods, facilities, and controls for manufacturing 361 HCT/Ps, primarily to prevent transmission of communicable disease. Current Good Manufacturing Practices (cGMP) are considerably more rigorous standards applied to pharmaceutical drugs and biologics, covering consistent safety, purity, and potency. Knowing which standard applies to a given product tells you how much manufacturing oversight actually sits behind it.

Question 9

How can I check whether a provider or tissue supplier has received FDA warning letters?

Accepted Answer

The FDA maintains a publicly searchable database of Warning Letters and Notices of Inspectional Observations. Search the provider name, the managing physicians, and the tissue manufacturer separately. Look for enforcement actions involving 21 CFR Part 1271 violations, marketing of unapproved biological drugs, or failure to follow Current Good Tissue Practices.

Question 10

Can any provider legally guarantee that a procedure will resolve my condition?

Accepted Answer

No. The Federal Trade Commission and state medical boards prohibit guaranteeing clinical outcomes. Biological response varies with age, metabolic health, structural damage, and factors that cannot be fully predicted in advance. Any provider promising guaranteed results or citing 100 percent success rates is engaged in deceptive marketing, and that single claim tells you most of what you need to know about how they operate.

Question 11

How do I verify the quality of the biologics a provider uses?

Accepted Answer

Request the Certificate of Analysis for the exact lot being used, issued by an independent CLIA-certified laboratory. A meaningful CoA verifies sterility testing, endotoxin testing, communicable disease screening, and cell viability measured close to the point of use. A general marketing brochure about product quality is not a CoA, and a provider who cannot produce one with a verifiable lot number is asking you to take the most important part of the procedure on faith.

Question 12

What exactly is a Certificate of Analysis?

Accepted Answer

It is a laboratory document detailing the specifications, purity, and safety profile of a specific tissue lot. It should confirm screening for infectious disease including HIV, Hepatitis B and C, and syphilis, along with testing for bacterial contamination. The lot number on the CoA should match the lot number of the product administered to you. That match is the entire point of the document.

Question 13

Why does the difference between TNC count and CFU-F matter?

Accepted Answer

Total Nucleated Cell count measures every cell with a nucleus in a sample, including dead cells, white blood cells, and debris. It is not a measure of regenerative potential. Colony-Forming Unit-Fibroblast is a functional assay measuring live cells actually capable of replicating and forming colonies. Marketing that advertises millions of cells based on TNC count alone is describing a number that may have little relationship to what is biologically active in the vial.

Question 14

How should cell products be stored and transported?

Accepted Answer

Products requiring cryopreservation must be held in vapor-phase liquid nitrogen below -150 degrees Celsius with continuous temperature monitoring, and frozen using controlled-rate protocols. If the cold chain breaks in transit or the receiving facility uses standard commercial freezers, cell membranes rupture and what remains is cellular debris. When evaluating a provider, ask about both the shipping protocol and the on-site storage equipment.

Question 15

Why does independent third-party lab testing matter?

Accepted Answer

Testing performed by the manufacturer of a product is subject to bias and to optimized conditions that may not reflect the product's state on arrival. Independent CLIA-certified laboratory testing produces objective data on sterility, endotoxin levels, and viability. The question worth asking is not whether a product was tested, but who did the testing and whether they had an interest in the result.

Question 16

What is the difference between autologous BMAC and allogeneic donor tissue?

Accepted Answer

Bone marrow aspirate concentrate is autologous, meaning harvested from your own body, processed the same day, and reinjected. It contains live mesenchymal and hematopoietic cells. Allogeneic perinatal tissue is donor-derived and processed, and different products vary substantially in what they contain. Independent analyses have found that some commercially available off-the-shelf perinatal products contain far fewer live cells than their marketing suggests. This is precisely why documented viability testing on the specific lot matters more than the category label.

Question 17

What should I know about exosomes?

Accepted Answer

Exosomes are acellular vesicles that cells release to transfer signaling molecules. They are an active area of research. There are currently no FDA-approved exosome products for clinical use in the United States, and the FDA has issued public safety alerts after unapproved exosome injections were linked to serious systemic infections and adverse reactions. Any provider discussing exosomes should be able to state that regulatory position plainly rather than presenting them as an established therapy.

Question 18

What qualifications should the physician performing the procedure have?

Accepted Answer

Board certification in a relevant specialty such as interventional orthopedics, physical medicine and rehabilitation, or sports medicine, along with documented fellowship training or specialized certification in image-guided procedures. For complex joint or spine work, a general practitioner or mid-level provider without interventional training is a meaningful gap in the standard of care.

Question 19

Why is image guidance considered mandatory for joint and spine procedures?

Accepted Answer

Injections placed by anatomical landmark alone miss the intended joint space or tissue structure a substantial share of the time, with published failure rates in the range of 30 to 40 percent for some targets and higher for complex spinal structures. A biologic only does anything where it is actually placed. Ultrasound for soft tissue and peripheral joints, and fluoroscopy for deep structures and spine, are how placement is verified rather than assumed.

Question 20

What should be evaluated before a provider accepts someone as a candidate?

Accepted Answer

A thorough evaluation reviews recent high-resolution imaging rather than basic X-rays, includes a physical examination relevant to the area of concern, and reviews bloodwork covering inflammatory markers, metabolic health, and screening for active infection or malignancy. A provider who can quote you a price before reviewing any of that is selling a procedure rather than evaluating a patient.

Question 21

How do age and metabolic health affect candidacy?

Accepted Answer

For autologous procedures using a patient's own cells, biological age and metabolic state directly affect the quality of the harvested material. Uncontrolled diabetes, significant obesity, and certain autoimmune conditions can reduce the colony-forming potential of bone marrow. This is a large part of why bloodwork belongs in a candidacy review, and why the honest answer for some patients is that they are not a good candidate.

Question 22

Why do NSAIDs and steroids need to be stopped before a procedure?

Accepted Answer

Non-steroidal anti-inflammatory drugs and systemic corticosteroids suppress the inflammatory signaling that biologic approaches depend on. Providers who understand the mechanism typically require a washout period, commonly two to four weeks before and after. A provider who does not ask what medications you take, or does not require a washout, is skipping a step that affects both safety and the underlying rationale.

Question 23

What are the risks of intravenous delivery of structural tissue products?

Accepted Answer

Delivering structural tissue products intravenously carries risk including pulmonary embolism and severe immune reaction. The FDA has issued repeated warnings about IV infusion of unapproved cellular products. IV administration of a product intended as a structural tissue is off-label use of a product outside its regulatory pathway, and it is a practice worth asking direct questions about.

Question 24

How should a provider track outcomes over time?

Accepted Answer

Standardized, validated patient-reported outcome measures, collected at defined intervals such as three, six, twelve, and twenty-four months. Instruments like the WOMAC index for knees or the Oswestry Disability Index for back pain produce comparable data over time. A provider whose entire evidence base is verbal testimonials collected shortly after the procedure has no way to know what actually happened to their patients.

Question 25

What should I expect a legitimate procedure to cost?

Accepted Answer

Cost varies widely by procedure type, complexity, biologic used, and location. In the U.S., image-guided orthobiologic procedures such as autologous BMAC or high-concentration PRP commonly fall in the range of a few thousand dollars per joint area. International programs are structured differently and often bundle multiple components into a single price. The number itself matters less than whether the provider will tell you clearly what is included, what is not, and what could be added later.

Question 26

What questions should I ask about pricing?

Accepted Answer

Ask what the quoted price covers and what it does not. Ask whether anything is billed separately, whether there are consultation or coordination fees, and whether any cost appears after you commit. Ask what happens financially if the evaluation determines you are not a candidate. A provider who answers all of that directly is behaving transparently regardless of what the number is. A provider who deflects is telling you something.

Question 27

Are these procedures covered by insurance or Medicare?

Accepted Answer

Generally no. Most commercial insurance and Medicare classify regenerative procedures as elective or investigational, which makes them out-of-pocket. Some plans may cover diagnostic imaging or an initial physician consultation while excluding the biologic and the procedure itself. Any provider suggesting they can get these procedures covered is worth a second look.

Question 28

What does predatory marketing look like in this field?

Accepted Answer

Common patterns include free dinner seminars built around fear of surgery, limited-time discounts contingent on signing immediately, non-disclosure agreements that prevent patients from posting negative reviews, and steering patients toward high-interest medical financing during the initial sales conversation. Add to that any guarantee of results, which is both an ethics violation and a truth-in-advertising violation.

Question 29

Why should I be skeptical of financing offered alongside guaranteed results?

Accepted Answer

Because the guarantee cannot be true. Human healing response is variable and no provider can promise an outcome. A guarantee attached to a financing application is a pressure structure designed to secure commitment before the patient has time to evaluate anything, and it violates both medical ethics and FTC standards on truth in advertising.

Question 30

What should I do if a provider claims a procedure will let me avoid a knee replacement?

Accepted Answer

Ask for a formal candidacy screening based on recent imaging before that conversation goes any further. Regenerative approaches are studied primarily in mild-to-moderate joint degeneration. They are not a substitute for surgical intervention in advanced, end-stage joint deterioration, and a provider promising otherwise is making a claim that current evidence does not support.

Industry questions any patient should be able to get answered.

Regulation & Legal Standing

Biologic Quality & Lab Verification

Ask the same questions of every clinic you speak to.

Clinical Standards & Delivery

Cost, Marketing & Ethics

The questions most clinics avoid. Ours are answered here.

Industry questions any patient should be able to get answered.

Regulation & Legal Standing

01How do I know if a stem cell provider is operating legally in the United States?

02What is the difference between an FDA-Registered facility and an FDA-Approved product?

03What does the FDA mean by 'minimal manipulation'?

04Why is injecting amniotic or perinatal tissue into a joint considered non-homologous use?

05Is it legal to offer IV infusions of cell products for anti-aging or general wellness?

06Can umbilical cord blood be marketed as a stem cell therapy for anti-aging?

07What is the Corporate Practice of Medicine doctrine, and why does it matter?

08What is the difference between cGTP and cGMP?

09How can I check whether a provider or tissue supplier has received FDA warning letters?

10Can any provider legally guarantee that a procedure will resolve my condition?

Biologic Quality & Lab Verification

11How do I verify the quality of the biologics a provider uses?

12What exactly is a Certificate of Analysis?

13Why does the difference between TNC count and CFU-F matter?

14How should cell products be stored and transported?

15Why does independent third-party lab testing matter?

16What is the difference between autologous BMAC and allogeneic donor tissue?

17What should I know about exosomes?

Ask the same questions of every clinic you speak to.

Clinical Standards & Delivery

18What qualifications should the physician performing the procedure have?

19Why is image guidance considered mandatory for joint and spine procedures?

20What should be evaluated before a provider accepts someone as a candidate?

21How do age and metabolic health affect candidacy?

22Why do NSAIDs and steroids need to be stopped before a procedure?

23What are the risks of intravenous delivery of structural tissue products?

24How should a provider track outcomes over time?

Cost, Marketing & Ethics

25What should I expect a legitimate procedure to cost?

26What questions should I ask about pricing?

27Are these procedures covered by insurance or Medicare?

28What does predatory marketing look like in this field?

29Why should I be skeptical of financing offered alongside guaranteed results?

30What should I do if a provider claims a procedure will let me avoid a knee replacement?

The questions most clinics avoid. Ours are answered here.